Overview

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride